CD8 Antigen-Binding Constructs for Precise T-Cell Targeting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing technologies lack effective antigen binding constructs that can specifically target and bind to CD8, a transmembrane glycoprotein crucial for T-cell activation and localization, which is essential for understanding immune responses and therapeutic targeting.
Innovation Solution
Development of antigen binding constructs such as humanized cys-diabodies and minibodies that include specific HCDR and LCDR sequences, capable of binding to CD8, along with methods for their use in detection and therapeutic targeting.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If antigen binding constructs are developed to specifically bind to CD8, then detection precision and therapeutic targeting capability are improved, but device complexity and manufacturing difficulty increase
Solution Approach 1:
The patent segments the antibody structure into variable domains (VH, VL) and constant domains (CH, CL), with further segmentation into CDR and framework regions. This allows independent optimization of binding specificity (using CDRs) and structural stability (using framework regions and constant domains), resolving the contradiction between detection precision and construct complexity.
Solution Approach 2:
The patent applies local quality by designing specific CDR regions with high variability for CD8 binding specificity while using conserved framework regions for structural support. The CDR1, CDR2, and CDR3 regions are optimized locally for antigen recognition, while the constant domains provide uniform structural properties, enabling precise detection without excessive overall complexity.
2Object-affected harmful factors
If humanized antibody constructs are used to reduce immunogenicity, then biocompatibility is improved, but manufacturing precision requirements increase
Solution Approach 1:
The patent changes the amino acid sequence parameters of the antibody constructs by humanizing the variable regions and optimizing CDR sequences. Specific sequence variations are introduced to reduce immunogenicity while maintaining CD8 binding affinity, requiring precise manufacturing control to ensure correct sequence expression and folding.
Solution Approach 2:
The patent creates composite antibody structures combining human framework regions with grafted CDR regions from other species. This composite approach reduces immunogenicity by using human-like structures while retaining antigen-binding capability, but requires high manufacturing precision to ensure proper assembly and conformation of the hybrid structure.
Data Source
AI summary
Antigen binding constructs that bind to CD8, for example antibodies, including antibody fragments (such as scFv, minibodies, and cys-diabodies) that bind to CD8, are described herein. Methods of use are described herein.